Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tiziana Life Sciences ( (TLSA) ) has provided an update.
On June 13, 2025, Tiziana Life Sciences announced that its CEO, Ivor Elrifi, will present at the Bio International Convention in Boston, discussing recent clinical findings of their lead drug candidate, intranasal foralumab. This drug, designed to treat neuroinflammatory and neurodegenerative diseases, is currently in Phase 2 trials for non-active Secondary Progressive Multiple Sclerosis and is progressing towards trials for early Alzheimer’s Disease. The announcement highlights Tiziana’s innovative approach and potential impact on treating these conditions, reinforcing its position in the biotechnology industry.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company specializes in alternative routes of immunotherapy, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. This innovative approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods.
Average Trading Volume: 380,970
Technical Sentiment Signal: Buy
Current Market Cap: $162.7M
Learn more about TLSA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue